Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026)

Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - 84.25%
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 32.96%
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 28.95%
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -49.71%
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - 20.92%
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 12.01%
9 Abivax 90.15 Bn 90.15 Bn - -
10 Halozyme Therapeutics 8.24 Bn 7.92 Bn 297.47 Mn 51.13%

Historic Data

Download Data
DateValue
Mar 31, 2026 51.13%
Dec 31, 2025 -50.73%
Sep 30, 2025 43.75%
Jun 30, 2025 89.72%
Mar 31, 2025 24.57%
Dec 31, 2024 48.15%
Sep 30, 2024 30.62%
Jun 30, 2024 8.76%
Mar 31, 2024 50.65%
Dec 31, 2023 11.37%
Sep 30, 2023 41.04%
Jun 30, 2023 53.27%
Mar 31, 2023 119.50%
Dec 31, 2022 59.46%
Sep 30, 2022 70.40%
Jun 30, 2022 59.46%
Mar 31, 2022 244.62%
Dec 31, 2021 218.46%
Sep 30, 2021 67.04%
Jun 30, 2021 81.75%